BPC-157 Benefits: The Most-Studied Healing Peptide

BPC-157 is the peptide people reach for when something will not heal. Think of a tendon that has been sore for months, a knee that flares up every time you train, or a gut that never quite settles. In animal and cell studies, it helps new blood vessels grow into slow-healing tissue such as tendon, ligament and the gut lining. It also makes cells respond more strongly to growth hormone. In people, the data so far comes from small pilot studies with no comparison group. It is banned in sport.

If you have looked into recovery peptides, BPC-157 is probably the first name you came across. Bodybuilders inject it near a sore tendon. Biohackers swallow it for gut trouble. It also has more research behind it than any other healing peptide. Most of that research is in animals, so this guide is clear about what has been shown in people and what has not.

This guide starts with what using it is actually like. It then covers what BPC-157 is, what the research supports, how people dose it, and how to use it safely. Primogen sells it on its own and inside three blends, so we want you to know exactly what you are buying.

What does BPC-157 actually do for you?

Here is what people report, in everyday terms, and roughly when.

• Injuries that are slow to heal. This is the main use. Users most often report less pain and easier movement around a tendon, ligament or joint injury within 2 to 4 weeks. Pain and movement tend to improve before the tissue itself has changed. Long-running tendon problems usually take longer, often 4 to 12 weeks.
• The gut. Swallowed, it mostly stays in the gut, which is why gut users take it by mouth rather than inject it. Some report their symptoms settling quickly, even in the first week.
• General recovery. Some users report less muscle soreness after training and an easier recovery after surgery. These are user reports.

What not to expect: it will not reattach a fully torn tendon or ligament, or fix a slipped or crushed disc. Those still need a doctor. And it works quietly. Most people notice the injury bothering them less, not a feeling from the peptide itself.

A few things can go the other way. A brief sting, redness or soreness where you inject is common, and it usually passes within a day or two. Headache, tiredness and an upset stomach (when swallowed) are occasional. A few users describe a flat or low mood, though no one has shown BPC-157 causes it. If you have cancer now, or had it recently, skip it, because it encourages new blood vessels to grow. We cover that further down.

What is BPC-157?

BPC-157 is a lab-made piece of a larger protein called Body Protection Compound (BPC). That protein was first found in human stomach juice. BPC-157 copies a 15-amino-acid section of it.

Its older name was "stable gastric pentadecapeptide". The word "stable" is the key part. Most peptides break down fast in stomach acid. BPC-157 is reported to stay intact for over 24 hours in stomach juice. That is why it can be studied as a swallowed dose for the gut. For most peptides, swallowing them does nothing.

It was first made by Pliva, a drug company in Croatia, under codes such as PL-14736. The goal was a treatment for inflammatory bowel disease (IBD), a long-term gut inflammation problem. That program later passed to Barr and then Teva, and was quietly dropped. This matters for the evidence, which is covered below.

How does BPC-157 work?

In animal and cell studies, BPC-157 seems to work in two main ways. It helps new blood vessels grow, and it makes tissue more responsive to growth hormone. Both show up in tendon studies and in gut studies. That is why the same peptide is studied for both connective tissue and the gut lining.

• New blood vessels. The science word for this is angiogenesis. BPC-157 is reported to turn up VEGFR2, a receptor that triggers blood-vessel growth. It also works through the nitric-oxide system, a signal that relaxes and widens blood vessels. Tendons and ligaments get very little blood. That is why researchers study BPC-157 for these slow-healing tissues.
• More growth hormone receptors. Fibroblasts are the cells that build connective tissue. In fibroblasts taken from rat Achilles tendons, BPC-157 raised the number of growth hormone receptors. This made the cells respond more to the body's own growth hormone (Chang et al., Molecules 2014). So BPC-157 is thought to boost the body's own growth hormone signal. It does not act like a growth hormone injection.
• Cell movement and gut protection. In lab work, BPC-157 switches on a cell signal called FAK-paxillin. This helps fibroblasts spread out and move into a wound. It also shifts macrophages, the immune cells that clean up damage, into repair mode. And it protects the gut lining (Sikiric et al., Front Pharmacol 2021). That gut-protecting effect is what the first Croatian IBD program was after.

What is BPC-157 researched for?

BPC-157 is studied in three main areas. The first is tendons, ligaments and joints. The second is the gut. The third is general tissue repair and wound healing. The biggest body of animal research is on muscles, tendons and joints. A few small human pilot studies exist for knee pain and bladder pain. Here is what each area looks like.

What is BPC-157 researched for in tendon, ligament and joint repair?

This is the main research area, and the most common reason people use BPC-157. Bodybuilders and athletes use it for sore tendons, rotator cuff (shoulder) problems, elbow pain and achy joints. They usually inject it sub-Q, meaning into the fat just under the skin, near the injury. The animal data on tendon and ligament healing is the strongest part of the research.

The best human result so far comes from a small pilot study. In Lee & Padgett 2021, 12 people with long-term knee pain got a single injection right into the knee joint. Of those 12, 11 reported clear relief. More than six months later, 7 of the 12 still had relief. That is the best published human result on how long the effect lasts. It was a small study that looked back at the records of 12 people, and it had no placebo group.

For how BPC-157 compares with the other big recovery peptide, see BPC-157 vs TB-500. In short, they are a pair, not a choice. BPC-157 works locally and fast. TB-500 works across the whole body and more slowly. That is why people so often run them together.

What is BPC-157 researched for in gut healing?

The gut is the signature research area for BPC-157. It is also the one place where taking it by mouth is studied seriously. People use it for IBS-type symptoms, "leaky gut", stomach damage from painkillers called NSAIDs, and gut upset after antibiotics. When swallowed, BPC-157 is reported to act directly on the gut lining. That is the reason this route is used in gut research. The first Pliva Phase 2 trial in ulcerative colitis (a type of IBD) reported that BPC-157 was safe and well tolerated. As covered below, the results on how well it worked were never published.

One practical point. Swallowed BPC-157 is studied as a local gut treatment. It is not reported to spread through the body to reach an injury somewhere else. So if your problem is a tendon, the studied route is an injection near it. If your target is the gut, take it by mouth. For gut use, some people take it on an empty stomach and wait about 30 minutes before eating. Others take it with food. It depends on how well they handle it.

What is BPC-157 researched for in general recovery and wellness?

The third area is broader. It covers general "body protection", recovery after surgery, and skin and wound healing. These studies often look at BPC-157 alongside GHK-Cu and TB-500. That is the idea behind the GLOW and KLOW blends. They pair BPC-157 with TB-500 and GHK-Cu, and KLOW also adds KPV. Together they cover tissue repair, skin and collagen, and gut inflammation research in one protocol.

What does the evidence on BPC-157 actually show?

BPC-157 has a huge amount of animal research and very little finished human data. No large human trial has been completed and published for any use. In people, there are only a few small pilot studies with no comparison group. Here is where the evidence stands.

• Animal studies: a large body of research covering tendon, ligament, muscle, gut, skin and more. A 2025 review (Vasireddi et al., HSS J 2025) screened 544 BPC-157 articles published between 1993 and 2024. A narrower PubMed search on 20 May 2025 found over 190. The safety margin in animals is wide. Researchers could not reach a lethal dose, even at very high amounts.
• One main research group: a large share of these papers come from one team, Sikiric and Seiwerth in Zagreb. A 2025 review (Jozwiak et al., Pharmaceuticals 2025) found that more than 80% of the published papers list those authors. Until other labs repeat the work, that limits how sure anyone can be about the findings.
• Human trials: there is no completed, published Phase 3 trial for any use. There is no completed, published Phase 2 trial either. The one properly sized Phase 2 (Pliva's ulcerative colitis trial) never published its results after the program was dropped. A Phase 1 trial in healthy volunteers (NCT02637284) withdrew its results in 2016, with no public reason given.
• Human pilot studies: there are three small recent studies. All come from the same Florida clinic, and none had a placebo group. One is the knee-pain study above, in 12 people. One looked at interstitial cystitis, a long-term bladder-pain condition, also in 12 people. It reported that symptoms cleared by 80 to 100% at six weeks (Lee et al. 2024). The third was an IV safety pilot in 2 people, with no side effects reported (Lee & Burgess 2025).

So here is the fair summary. BPC-157 is the most-studied healing peptide by volume, and the way it works makes sense. The human evidence is still early, and those studies had no comparison group. The animal research also leans heavily on one lab, with more than 80% of papers from the same group. Both things are true at once.

How do you dose BPC-157?

The usual range is 250 to 500 mcg a day, run in 4 to 8 week blocks. People inject it under the skin for whole-body or local recovery. They take it by mouth when the target is the gut. These figures come from community and practitioner use, not a medical prescription. They match standard allometric scaling from the rat studies. That is the maths used to turn an animal dose into a human dose based on body size.

• General recovery (whole body): 250 to 500 mcg a day under the skin, often split into a morning and an evening dose.
• Fresh muscle or joint injury: a higher starting range early on (up to about 600 to 1,000 mcg a day), injected near the injury, then tapered down.
• Gut: 250 to 500 mcg a day, by mouth or under the skin. By mouth is the studied route when the target is the gut itself.

A worked mixing example. Take a 5 mg vial and add 2 mL of bacteriostatic water. That gives 5,000 mcg in 2 mL, or 2,500 mcg per mL. A standard insulin syringe is marked 0 to 100 units across 1 mL. So 1 mL, or 100 units, holds 2,500 mcg, and each unit holds 25 mcg. A 250 mcg dose is 10 units (0.1 mL). A 500 mcg dose is 20 units (0.2 mL). At 250 mcg a day, that 5 mg vial gives you 20 doses.

You take BPC-157 every day because it does not last long in the blood. Its half-life is the time it takes for half of it to clear the blood. In rat and dog studies, that was under about 30 minutes (He et al., Front Pharmacol 2022). Some sellers quote a "4-hour half-life", but no published study backs that figure. A better explanation is that its effects on the body's signals last longer than the peptide stays in the blood.

For the practical steps, see our full guide on how to reconstitute and dose. It covers mixing with bacteriostatic water, swirling (not shaking), drawing up and injecting. Two points are specific to BPC-157. First, use bacteriostatic water only. Second, do not mix it in the same vial with TB-500 or GHK-Cu yourself. The binders and preservatives can weaken it. A ready-made blend like the BPC-157 + TB-500 product is different, because the maker has made it stable. It is the exception, not a reason to mix your own in one vial.

How long should you cycle BPC-157?

Run it in blocks, not all year. Common patterns are 4 weeks on and 4 off, or 8 weeks on and 8 off. Tie it to a real injury or goal, and do not run it nonstop for more than about 12 weeks. Community users and the practitioner sources in our knowledge base agree on this. Treat it as a tool for a set period, not something you take forever.

• 4 weeks on, 4 weeks off, or 8 weeks on, 8 weeks off.
• For a fresh injury, run it until the injury heals, then stop.
• Do not run it nonstop for more than about 12 weeks.

There are two reasons for this. One is caution about its effects on blood vessels. The other is that there is no long-term human safety data beyond 12 months. Surgery is a mixed picture. Some people run BPC-157 around an operation. Others hold off for the first week or two afterwards. That lets the body's own early inflammation do its job first. There is no human data either way. So talk to the surgeon who knows your case before using it around an operation.

What are the side effects and safety risks of BPC-157?

In animals and small human studies, BPC-157 is generally well tolerated. Standard blood tests stay mostly unchanged, and the safety margin in animals is wide. There is no long-term human safety data. These are the main safety points to know.

• Cancer caution. No study has shown that BPC-157 causes cancer. Lab tests for DNA damage came back negative. The concern comes from how it works, not from anything that has been seen. The same blood-vessel and growth signals it uses for repair can also be used by tumours. Our sources agree on the practical advice. Do not use BPC-157 if you have cancer now or were treated for it recently. Before a long course, get the cancer screening that suits your age and risk. Take extra care if you combine it with growth hormone or drugs that raise growth hormone.
• Product quality and endotoxin. Poorly made "research only" peptides can carry LPS, also called endotoxin. It is a toxin shed by bacteria. It causes inflammation and, in the worst case, can trigger severe reactions. A clean product is your safety margin here. Check the certificate of analysis (COA) on whatever you buy.
• It does not fix structural damage. BPC-157 is studied for tissue repair. It is not reported to reattach a fully torn tendon or ligament, or fix a herniated (slipped) disc. Those need a proper diagnosis with scans, and structural treatment. Reaching for a peptide instead of a scan on a suspected full tear is how people lose time.
• Mood and dopamine. Some animal studies touch on mood. There are also reports that it may weaken stimulants that act on the brain's dopamine system, such as Adderall or modafinil. The animal studies suggest it evens out mood rather than lowering it. In people, the picture is mixed and unproven either way.
• Reported by users: pain, redness or a burning feeling at the injection site for a day or two. Now and then, headache or tiredness, or mild nausea with the oral form.

Is BPC-157 banned in sport?

Yes. BPC-157 is on the WADA Prohibited List under S0, the group for non-approved substances. It is banned at all times, in and out of competition. No therapeutic use exemption is available (WADA 2025 Prohibited List, S0). It shows up in urine tests for several days (Cox et al., Drug Test Anal 2017). Athletes have been penalised for it. If you are drug-tested in any way, do not use it.

Where does BPC-157 fit in your stack?

You can run BPC-157 on its own for a tendon, ligament or gut target. You can pair it with TB-500 for fast local repair plus whole-body support. Or you can use it inside the GLOW and KLOW blends with GHK-Cu (and KPV), when the goal also covers skin and collagen. Here is the breakdown.

• On its own: the usual first choice for a tendon, ligament or gut target.
• With TB-500: the classic recovery pair. BPC-157 is local and fast. TB-500 works across the whole body and more slowly. We stock them as a ready-mixed BPC-157 + TB-500 vial. Full comparison in BPC-157 vs TB-500.
• With GHK-Cu (and KPV): for recovery plus skin, collagen and gut. This is what the GLOW and KLOW blends are built around. GLOW is BPC-157 + GHK-Cu + TB-500. KLOW adds KPV.

Referenced products

BPC-157

Rp 1.490.000 · 10mg

BPC + TB Blend

Rp 2.190.000 · 20mg

GLOW Blend

Rp 2.990.000 · 70mg

KLOW Blend

Rp 3.290.000 · 80mg